Quarterly ResultMay 7, 2026, 05:22 PM
Guardant Health Q1 Revenue $301.7M; Net Loss $(112.1)M
AI Summary
Guardant Health reported a significant increase in revenue for the first quarter ended March 31, 2026, reaching $301.7 million, a 48.3% rise year-over-year. This growth was primarily driven by strong performance in oncology and a substantial surge in screening revenue. However, the company's net loss also expanded to $(112.1) million, up from $(95.2) million in the same period last year, resulting in a diluted net loss per share of $(0.85).
Key Highlights
- Revenue increased 48.3% to $301.7 million for the three months ended March 31, 2026.
- Net loss expanded 17.8% to $(112.1) million for the quarter.
- Diluted net loss per share was $(0.85), compared to $(0.77) in the prior year.
- Oncology revenue grew 36.1% to $205.0 million.
- Screening revenue surged 632.6% to $41.6 million.
- Net cash provided by investing activities was $699.4 million.
- Cash and cash equivalents increased to $989.3 million as of March 31, 2026.
Price Impact
More from GH